Women in the KwaZulu-Natal province of South Africa are signing up for the safety and efficacy trials of a microbicide gel, formulated with the antiretroviral tenofovir, which researchers hope will protect them from contracting HIV. If the gel works, it will be a major step forward in the quest for a female-controlled product to prevent infection.
For the free full text of this article see here http://www.thelancet.com/journals/lancet/article/PIIS0140673607610290/fulltext. Remember that you have to register with The Lancet to view their content. Registration is free and quick.
